Caprius enters diagnostics market

Article

Caprius of Fort Lee, NJ, completed its exit from the medical imaging field by acquiring an in vitro diagnostics company in late June. Caprius announced that it had acquired Opus Diagnostics and intends to market a line of therapeutic drug monitoring

Caprius of Fort Lee, NJ, completed its exit from the medical imaging field by acquiring an in vitro diagnostics company in late June. Caprius announced that it had acquired Opus Diagnostics and intends to market a line of therapeutic drug monitoring products. Caprius previously marketed the Aurora breast MRI scanner until it sold that business in April to Pacific Republic Capital of Newport Beach, CA (SCAN 5/12/99). As part of the deal, several Opus executives have been appointed to lead Caprius. Caprius’ long-time chairman and CEO, Jack Nelson, will be leaving the company, as will president Enrique Levy.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.